新型靶向治疗的临床前研究。
Preclinical studies of novel targeted therapies.
作者信息
Hideshima Teru, Anderson Kenneth C
机构信息
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
出版信息
Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. doi: 10.1016/j.hoc.2007.08.013.
Abstract
The bone marrow (BM) milieu confers drug resistance in multiple myeloma (MM) cells to conventional therapies. Novel biologically based therapies are therefore needed. Preclinical studies have identified and validated molecular targeted therapeutics in MM. In particular, recognition of the biologic significance of the BM microenvironment in MM pathogenesis and as a potential target for novel therapeutics has already derived several promising approaches. Thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) are directed not only at MM cells but also at the BM milieu and have moved rapidly from the bench to the bedside and United States Food and Drug Administration approval to treat MM.
摘要
骨髓（BM）微环境赋予多发性骨髓瘤（MM）细胞对传统疗法的耐药性。因此，需要新型的基于生物学的疗法。临床前研究已经在MM中鉴定并验证了分子靶向疗法。特别是，认识到BM微环境在MM发病机制中的生物学意义以及作为新型疗法的潜在靶点，已经衍生出了几种有前景的方法。沙利度胺、来那度胺（瑞复美）和硼替佐米（万珂）不仅作用于MM细胞，还作用于BM微环境，并且已经迅速从实验室走向临床，并获得了美国食品药品监督管理局的批准用于治疗MM。
相似文献
1
Preclinical studies of novel targeted therapies.新型靶向治疗的临床前研究。
Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. doi: 10.1016/j.hoc.2007.08.013.
2
Recent advances in the treatment of Multiple Myeloma.多发性骨髓瘤治疗的最新进展
Curr Pharm Biotechnol. 2006 Oct;7(5):381-93. doi: 10.2174/138920106778521569.
3
Multiple myeloma.多发性骨髓瘤
Hematology Am Soc Hematol Educ Program. 2004:237-56. doi: 10.1182/asheducation-2004.1.237.
4
The malignant clone and the bone-marrow environment.恶性克隆与骨髓环境。
Best Pract Res Clin Haematol. 2007 Dec;20(4):597-612. doi: 10.1016/j.beha.2007.08.002.
5
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.在SN38介导的对多发性骨髓瘤的细胞毒性作用中，拓扑异构酶I的蛋白酶体降解之前会发生c-Jun氨基末端激酶激活、Fas上调和聚（ADP-核糖）聚合酶裂解。
Cancer Res. 2004 Dec 1;64(23):8746-53. doi: 10.1158/0008-5472.CAN-04-2894.
6
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.基于肿瘤微环境相互作用的多发性骨髓瘤靶向治疗
Exp Hematol. 2007 Apr;35(4 Suppl 1):155-62. doi: 10.1016/j.exphem.2007.01.024.
7
Proteasome inhibitor therapy in multiple myeloma.多发性骨髓瘤中的蛋白酶体抑制剂疗法
Mol Cancer Ther. 2005 Apr;4(4):686-92. doi: 10.1158/1535-7163.MCT-04-0338.
8
Novel therapies in MM: from the aspect of preclinical studies.新型多发性骨髓瘤治疗药物：从临床前研究角度看。
Int J Hematol. 2011 Oct;94(4):344-354. doi: 10.1007/s12185-011-0917-5. Epub 2011 Sep 1.
9
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.骨髓瘤细胞在体内骨髓微环境中表现出蛋白酶体活性增加以及对蛋白酶体抑制的反应增强。
Am J Hematol. 2009 May;84(5):268-72. doi: 10.1002/ajh.21374.
10
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.来那度胺和泊马度胺对多发性骨髓瘤肿瘤细胞与骨髓辅助细胞相互作用的免疫调节作用。
Blood. 2010 Oct 28;116(17):3227-37. doi: 10.1182/blood-2010-04-279893. Epub 2010 Jul 22.
引用本文的文献
1
Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.随机Ⅱ期临床试验：来那度胺治疗毛细胞型星形细胞瘤和视神经胶质瘤患儿——来自儿童肿瘤协作组的报告。
J Clin Oncol. 2023 Jun 20;41(18):3374-3383. doi: 10.1200/JCO.22.01777. Epub 2023 May 1.
2
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.多发性骨髓瘤中对现行标准治疗产生耐药性的生物学背景。
Cells. 2019 Nov 13;8(11):1432. doi: 10.3390/cells8111432.
3
Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.硼替佐米通过上调人骨髓间充质基质/干细胞中的SPARC来干扰B细胞前体急性淋巴细胞白血病细胞的黏附。
Int J Hematol. 2017 May;105(5):587-597. doi: 10.1007/s12185-016-2169-x. Epub 2017 Jan 2.
4
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.基于环氧酮的蛋白酶体抑制剂卡非佐米和口服生物利用度的奥普佐米除了具有抗骨髓瘤作用外，还具有抗吸收和促进骨形成的活性。
Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.
5
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.儿童复发性、难治性或进行性原发性中枢神经系统肿瘤患者接受来那度胺的 I 期临床试验：儿科脑瘤合作研究 PBTC-018。
J Clin Oncol. 2011 Jan 20;29(3):324-9. doi: 10.1200/JCO.2010.31.3601. Epub 2010 Dec 13.
6
Mechanism of action of immunomodulatory agents in multiple myeloma.免疫调节剂在多发性骨髓瘤中的作用机制。
Med Oncol. 2010 Jun;27 Suppl 1(Suppl 1):S7-13. doi: 10.1007/s12032-010-9527-y. Epub 2010 Apr 20.
7
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.姜黄素在体外可克服化疗耐药性，并增强沙利度胺和硼替佐米对裸鼠模型中人类多发性骨髓瘤的治疗效果。
Mol Cancer Ther. 2009 Apr;8(4):959-70. doi: 10.1158/1535-7163.MCT-08-0905.
8
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.头颈部癌细胞系中硼替佐米的敏感性差异与蛋白酶体、核因子-κB和活化蛋白-1相关机制有关。
Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.
本文引用的文献
1
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.抑制Akt可显著下调人多发性骨髓瘤细胞中生存素的表达并诱导其细胞毒性。
Br J Haematol. 2007 Sep;138(6):783-91. doi: 10.1111/j.1365-2141.2007.06714.x.
2
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.了解骨髓中多发性骨髓瘤的发病机制以确定新的治疗靶点。
Nat Rev Cancer. 2007 Aug;7(8):585-98. doi: 10.1038/nrc2189.
3
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.蛋白酶体新型不可逆抑制剂PR-171的抗肿瘤活性
Cancer Res. 2007 Jul 1;67(13):6383-91. doi: 10.1158/0008-5472.CAN-06-4086.
4
Bortezomib inhibits human osteoclastogenesis.硼替佐米抑制人破骨细胞生成。
Leukemia. 2007 Sep;21(9):2025-34. doi: 10.1038/sj.leu.2404806. Epub 2007 Jun 21.
5
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.热休克蛋白抑制与骨髓瘤浆细胞中未折叠蛋白反应途径的激活相关。
Blood. 2007 Oct 1;110(7):2641-9. doi: 10.1182/blood-2006-11-053728. Epub 2007 May 24.
6
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.靶向MEK可诱导骨髓瘤细胞产生细胞毒性并抑制破骨细胞生成。
Blood. 2007 Sep 1;110(5):1656-63. doi: 10.1182/blood-2007-03-081240. Epub 2007 May 17.
7
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.ABT-737是一种Bcl-2家族蛋白抑制剂，是多发性骨髓瘤细胞凋亡的有效诱导剂。
Leukemia. 2007 Jul;21(7):1549-60. doi: 10.1038/sj.leu.2404719. Epub 2007 Apr 26.
8
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.靶向β-连环蛋白/TCF转录复合物治疗多发性骨髓瘤。
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7516-21. doi: 10.1073/pnas.0610299104. Epub 2007 Apr 23.
9
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.分化与应激反应因子XBP-1驱动多发性骨髓瘤发病机制。
Cancer Cell. 2007 Apr;11(4):349-60. doi: 10.1016/j.ccr.2007.02.015.
10
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.蛋白酶体抑制剂硼替佐米在体外和体内均会影响多发性骨髓瘤患者的成骨细胞分化。
Blood. 2007 Jul 1;110(1):334-8. doi: 10.1182/blood-2006-11-059188. Epub 2007 Mar 19.
Zotero 插件